Congreso ARC en EPOC Madrid Octubre 2016. Mesa 1. Epidemiología , Diagnóstico, y Seguimiento del paciente con EPOC

1. Hospital Universitario de Bellvitge.
L’Hospitalet de Llobregat (Barcelona)
Dr. Joan Valldeperas

2. [ERS] The healthcare burden of non-compliance
to pharmacotherapeutic escalation
recommendations for COPD
Tavares R, Zhang S, Dang-Tan T, Ismaila A,
Stutz M, Coletta N, et al.
Mesa 1

4. To describe the healthcare burden associated with not escalating patients with COPD managed with
LAMA or LABA monotherapy or LAMA/LABA dual therapy to ICS/LAMA/LABA following a moderate
or severe exacerbation.
This observational study utilised medical claims from the Quebec Provincial Health Insurance
administrative database.
Included were patients ≥40 years of age with an incident diagnosis of COPD (during 2002–2011)
receiving a respiratory medicine within 2 weeks of a COPD claim and treated with a LAMA, LABA or
LAMA/LABA without a preceding moderate or severe exacerbation in 2 years preciding.
The study cohort were followed for a median of 3.56 years after the first exacerbation.
Multivariate-adjusted outcomes included incidence density rates for moderate or severe COPD
exacerbations and healthcare utilisation, stratified by escalation to ICS/LAMA/LABA triple therapy
following an exacerbation.
.

5. Tasa de densidad de incidencia

6. Overall, 19,198 (49.5%) patients experienced COPD
exacerbations.
Of these, 1,136 (5.9%) were escalated to triple therapy following
an exacerbation.
Compared with patients switched to triple therapy, those not
escalated experienced increased mean incidence density rates
(per 100 person-years) for future exacerbations (any: 0.21 vs
0.18, p<0.001; moderate: 0.10 vs 0.07, p<0.001), ER visits (0.11 vs
0.10, p<0.05), and greater use of antibiotics, oral corticosteroids
and rescue medications (0.94 vs 0.79, 0.76 vs 0.66, 1.08 vs 0.50;
p<0.001).
Hospitalisation rates were similar among patients treated with
triple therapy.
Other outcomes were similar between groups.
.

7. Failure to escalate to ICS/LAMA/LABA triple therapy
following an exacerbation results in increased
exacerbations, ER visits and concomitant medication
use in patients with COPD.
Funded by GSK: HO-13-14097.

8. [ERS] The healthcare burden of non-compliance
to pharmacotherapeutic escalation
recommendations for COPD
Rivera-Ortega P, González J, Restituto P, Varo N, Colina I, et al.
Mesa 1

9. Smoking Definitions
Never Smokers – Adults who have never smoked a
cigarette or who smoked fewer than 100 cigarettes
in their entire lifetime.
Former Smokers – Adults who have smoked at least
100 cigarettes in their lifetime, but say they currently
do not smoke.
Nonsmokers – Adults who currently do not smoke
cigarettes, including both former smokers and never
smokers.
Current Smokers – Adults who have smoked 100
cigarettes in their lifetime and currently smoke
cigarettes every day (daily) or some days (nondaily).